The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

For decades, the medical approach to treating obesity in children was the wait-and-see approach. But a new Canadian guideline ...

Novo Nordisk said it had been able to ease some of the restrictions on the supply of starting doses of Wegovy, starting with the US, that were introduced to try to cope with the massive demand for ...

Wegovy (semaglutide) has already been approved ... and Novo Nordisk said it would reduce production of the lower starting doses of the drug, restricting new starts on therapy, so make sure it ...